What are the obstacles to innovation in the pharmaceutical industryThe Pistoia Alliance
Perhaps the best possible deployment of gained trust is using those gains to drive even greater ambition. The pharmaceutical industry has the opportunity to use the accrued capital of public sentiment to ‘double-down’ on its formidable efforts of the last 2 years and invest in doing the ‘har...
The pharmaceutical industry in the United States is a powerhouse of innovation and one of the largest in the world. In fact, the USA is among the world’s largest producers and exporters of pharmaceutical products, contributing significantly to the country’s economy. Although many associate the ...
Fill finish has historically been an area with a focus on “proven solutions” and less innovation. However, this is changing due to shifts in the pharmaceutical industry. A growing trend of small batch sizes is pushing manufacturers toincrease the level of flexibility of aseptic production. Proce...
The premise of cGMP is that the quality system is based on the principles of Quality by Design instead of Quality by Inspection. If you’ve been in the pharmaceutical industry for a decade or more, you will recognize that “design over inspection” is a relatively new principle within current...
Pharmaceutical, as an adjective, refers to anything related to the preparation, use, or sale of medicinal drugs. Pharmaceutics is a noun that specifically denotes the science of preparing and formulating drugs for effective use.
GMP constitutes the license to operate in pharmaceutical manufacturing and is a core condition worldwide. However, rules and interpretations differ from country to country and change frequently. Therefore, having fully trained experts at hand to help with the implementation of these rules is very impo...
The journalist Ian Leslie, in his new and enjoyable book Curious: The Desire to Know and Why Your Future Depends on It, insists that the answer to that last question is “Yes”. Leslie argues that curiosity is a much-overlooked human virtue, crucial to our success, and that we are losin...
The regulatory changes these reforms have brought are going to catalyze the pharmaceutical industry in China, if their ambitions are realized (see sidebar, “Reforming the CFDA”). Second is R&D infrastructure. I have seen some promising examples in “innovating the way we do R&D” in China. ...
date of December 2015 implementation for the USP—many in the industry are both frustrated and confused as to how to proceed to prepare their companies and products to comply with what certainly promise to be significant changes in the way metals analysis in the pharmaceutical industry is ...